Shares of Sanofi Consumer Healthcare rallied as much as 16% to hit an intraday high of ₹4,649.90 on the National Stock Exchange (NSE) on Thursday, February 26, following the company's robust quarterly results announcement. According to CNBC TV18, the stock was trading with gains of 14.8% at ₹4,601 per equity share around 10:55 am, making it one of the top performers on the Nifty 500 index. The strong market response reflects investor confidence in the company's impressive financial performance and strategic initiatives. The scrip has jumped 14% in the past week and 13% over the month, with the stock touching a 52-week low of ₹3,975 on February 24, 2026, and hitting a year's peak of ₹5,894.50 on June 30, 2025.
The company reported a 50.11% year-on-year rise in net profit to ₹66.5 crore for the fourth quarter of CY25, as reported by CNBC TV18. In the same period last year, it had logged a profit of ₹44.3 crore, as stated in a regulatory filing dated February 25. Revenue from operations for the quarter came in at ₹251 crore, marking a robust 47% increase compared with ₹171 crore in the fourth quarter of CY24. The strong performance was driven by product relaunches and strong export growth, with the company benefiting from the relaunch of recalled products in the market. Domestic sales grew by 23%, supported by the relaunch of recalled products to the market, while export sales surged by 9.3 times due to a low base. However, the company's margin narrowed to 35.8% from 36.5% in the year-ago period, according to CNBC TV18.
For the full year 2025, Sanofi Consumer Healthcare reported revenue of ₹878.4 crore, reflecting 21% growth over the previous year, according to Upstox. Profit after tax for the year stood at ₹240.1 crore, up 33% year-on-year, supported by disciplined cost management and an improved product mix. The company's domestic sales increased by 7% YoY for the calendar year, while export sales soared by 158% YoY. The board of directors recommended a final dividend of ₹75 per equity share with a face value of ₹10 each for FY25, subject to shareholder approval at the ensuing annual general meeting (AGM), as confirmed by CNBC TV18. The company shall inform in due course the record date/book closure for payment of dividend.
Export performance showed significant improvement with export sales surging 9.3 times year-on-year in Q4, as reported by Upstox. For FY25, export sales rose 158% year-on-year, again reflecting the impact of a subdued base. The company's domestic business delivered healthy double-digit growth for two successive quarters, complemented by strong contributions from export markets. Management highlighted continued investment in brands and focus on operational excellence to unlock the next phase of sustainable growth.
According to CNBC TV18, Sanofi Consumer Healthcare shares have been underperformers over the last six months, declining 10% during this period. In contrast, the stock has gained 14% in the past week and 13% over the month, demonstrating recent recovery momentum. The company's performance contrasts with other market leaders, as KSB Ltd. emerged as the second-best performer on the Nifty 500 index with gains of 11% following its strong Q3 results, highlighting the varied investor sentiment across different sectors and company fundamentals.
